Eli Lilly and Company UK (NYSE: LLY) - Lilly's Lower-Priced Insulin Now Available -- 22/5/2019.
INDIANAPOLIS, May 22, 2019 /PRNewswire/--Eli Lilly and Company's (NYSE: LLY) Insulin Lispro Injection is now available for order in pharmacies for people who use Lilly's rapid-acting insulin and need a lower-cost option. Lilly's Insulin Lispro Injection has a 50 percent lower list price than its identical medicine, Humalog[R] U-100 (insulin lispro injection) and is available in both a vial and KwikPen[R]. Because they are the same insulin, pharmacists will be able to substitute Insulin Lispro Injection for Humalog.
In March, Lilly announced plans to introduce Insulin Lispro Injection, which fills another gap in the healthcare system. The people who are most likely to benefit from Insulin Lispro Injection are Medicare Part D beneficiaries, people with high-deductible health plans and the uninsured who use Humalog.
"The availability of Lilly's Insulin Lispro Injection is important progress that helps more people afford their insulin," said Mike Mason, senior vice president, Connected Care and Insulins. "Lilly will continue to work with health plans, wholesalers, employers and the government to work toward permanent solutions that will help every person with diabetes afford their medicines."
Currently, about 95 percent of people in the U.S. pay $95 or less a month for their Humalog prescription and 43 percent pay $0 at the retail pharmacy. With the launch of Insulin Lispro Injection, even more people will pay lower amounts at the pharmacy. Because most insurance plans provide affordable copays for chronic medicines that are much lower than list price, people should ask their pharmacist whether Insulin Lispro Injection or Humalog is the lower-cost option for them. People with additional questions can also contact the Lilly Diabetes Solution Center at (833) 808-1234 from 9 am to 8 pm EST Monday through Friday to speak with a live representative.
Insulin Lispro Injection has a list price of $137.35 per vial and $265.20 for a package of five KwikPens. In addition to wholesaler contracts that have been secured, Lilly is working with payers to gain broad insurance coverage for Insulin Lispro Injection.
"The current healthcare system isn't working for everyone, causing a growing number of people with chronic conditions to struggle to afford their medicine," Mason said. "But even one person with diabetes who can't afford insulin is too many, which is why we introduced Insulin Lispro Injection. It adds to our suite of solutions that help significantly lower the amount people pay until a more sustainable solution is achieved."
Indication for Humalog[R] (insulin lispro) and Insulin Lispro Injection
Humalog and Insulin Lispro Injection are used to treat people with diabetes for the control of high blood sugar.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Media Releases|
|Publication:||United Kingdom Pharmaceuticals|
|Date:||May 29, 2019|
|Previous Article:||GlaxoSmithKline (LSE: GSK) - GSK announces approval of Shingrix in China for prevention of shingles in adults aged 50 and over -- 23/5/2019.|
|Next Article:||AstraZeneca - Trial reflecting real-world practice showed a reduction in the rate of asthma attacks compared to the most commonly used reliever...|